http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정정기사 : Corrigendum: HBeAg 양성 만성간염 환자에서 항바이러스 치료 중단 후 지속적인 관해에 대한 예측 인자
전백규 ( Baek Gyu Jun ),이세환 ( Sae Hwan Lee ),김홍수 ( Hong Soo Kim ),김상균 ( Sang Gyune Kim ),김영석 ( Young Seok Kim ),김부성 ( Boo Sung Kim ),정승원 ( Soung Won Jeong ),장재영 ( Jae Young Jang ),김영돈 ( Young Don Kim ),천 대한소화기학회 2016 대한소화기학회지 Vol.67 No.2
경동맥화학색전술과 정위절제방사선 병합치료로 완전한 관해를 보인 작은 크기의 간세포암종 1예
차준영 ( Jun Young Cha ),전백규 ( Baek Gyu Jun ),공은정 ( Eun Jeong Gong ),서현일 ( Hyun Il Seo ),박종규 ( Jong Kyu Park ),이상진 ( Sang Jin Lee ),김영돈 ( Young Don Kim ),한군희 ( Koon Hee Han ),정우진 ( Woo Jin Jeong ),천갑진 ( 대한간암학회 2018 대한간암학회지 Vol.18 No.2
In hepatocellular carcinoma (HCC), surgical resection or local ablation therapy is limited because of severe liver dysfunction or tumor location. Transarterial chemoembolization (TACE) has beed used widely as palliative treatment. Stereotactic Body Radiotherapy (SBRT) is a more recent and effective treatment for early stage HCC. We report a case with small HCC with complete response by TACE combined with SBRT. (J Liver Cancer 2018;18:157-161)
HBeAg 양성 만성간염 환자에서 항바이러스 치료 중단 후 지속적인 관해에 대한 예측 인자
박재우 ( Park jae woo ),전백규 ( Baek Gyu Jun ),김홍수 ( Hong Soo Kim ),김상균 ( Sang Gyune Kim ),김영석 ( Young Seok Kim ),김부성 ( Boo Sung Kim ),정승원 ( Soung Won Jeong ),장재영 ( Jae Young Jang ),김영돈 ( Young Don Kim ),천 대한소화기학회 2016 대한소화기학회지 Vol.67 No.1
Background/Aims: The optimal timing for discontinuing oral antiviral therapy in patients with HBeAg-positive chronic hepatitis B (CHB) is unclear. The aim of our study was to investigate sustained remission after stopping antiviral therapy in patients with HBeAg-positive CHB.Methods: We analyzed the medical records of 58 patients who were HBeAg-positive and had discontinued antiviral therapy.Antiviral therapy was discontinued after HBeAg seroconversion and HBV DNA negativity for 6-12 months with consolidation therapy. Virologic relapse was defined as an increase in serum HBV DNA >2,000 IU/mL.Results: No difference was observed between the virologic non-relapse and virologic relapse groups in baseline HBV DNA level (p=0.441) or duration of seroconversion (p=0.070). Time-to-undetectable HBV DNA during treatment was shorter in the virologic non-relapse group (29 patients) compared to the relapse group (29 patients) (4.9±2.6 vs. 13.2±12.7 months; p<0.01).Cumulative relapse rates were 12.7 in month 3, 32.7 in month 6, 47.3 in month 12, and 52.7% in month 18. We determined by multivariate analysis that the consolidation period (≥18 months, p=0.020) and early virologic response (HBV DNA <20 IU/mL) at six months during antiviral therapy (p=0.017) were significant predictors for sustained remission.Conclusions: A consolidation period of at least 18 months and early virological response at six months during antiviral therapy were associated with sustained remission in patients with HBeAg-positive CHB after treatment.(Korean J Gastroenterol 2016;67:28-34)
이한민 ( Han Min Lee ),모상일 ( Sang Il Mo ),조현욱 ( Hyun Wook Cho ),이수진 ( Su Jin Lee ),전백규 ( Baek Gyu Jun ),김기원 ( Ki Won Kim ),김재원 ( Jae Yun Kim ),김영일 ( Young Il Kim ),나성수 ( Seong Su Na ) 대한류마티스학회 2013 대한류마티스학회지 Vol.20 No.1
Q 발열은 Coxiella burnetii 감염에 의해 발생하는 인수공통전염이다. 감염 시 두통, 오한, 발열, 전신무력감, 근육통 등의 감기유사증상부터 폐렴, 간염, 뇌수막염, 심막염, 심근염까지 다양한 임상 증상을 나타낸다. Q 발열의 임상 경과 중 흔히 자가항체가 발견되면서 자가면역질환의 진단기준을 만족시키기도 한다. 자가항체가 양성인 경우라도 발열이 지속되면서 혈액 세균배양검사에서 음성인 경우는 Q 발열도 감별진단으로 고려해 보아야 할 것이다. Q fever is a zoonosis caused by a Coxiella burnetii. Q fever is clinically variable, presenting as asymptomatic infection, pneumonia, hepatitis and endocarditis. Treatment of acute Q fever with doxycycline is usually successful. Autoantibodies, such as anti-mitochondrial antibodies, smooth muscle antibodies (SMA), anti-cardiolipin and lupus anticoagulant, often rise in acute Q fever infection. Some cases may occasionally meet the criteria for autoimmune disease like systemic lupus erythematosus. We report a first case of Q fever that may mimic systemic lupus erythematosus in Korea.
약제 내성 만성 B형간염 환자에서 테노포비어를 포함한 구원치료의 효과
박재우 ( Park jae woo ),천갑진 ( Gab Jin Cheon ),최강혁 ( Kang Hyug Choi ),이한민 ( Han Min Lee ),전백규 ( Baek Gyu Jun ),김홍수 ( Hong Soo Kim ),김상균 ( Sang Gyune Kim ),김영석 ( Young Seok Kim ),김부성 ( Boo Sung Kim ),정승원 ( 대한소화기학회 2015 대한소화기학회지 Vol.65 No.1
Background/Aims: Tenofovir disoproxil fumarate (TDF) plays a pivotal role in the management of drug-resistant chronic hepatitis B. However, it remains unclear whether TDF-nucleoside analogue combination therapy provides better outcomes than TDF monotherapy. This study aimed to compare the efficacy of TDF monotherapy with that of TDF-nucleoside analogue combination therapy in patients with drug-resistant chronic hepatitis B. Methods: This retrospective cohort study included 76 patients receiving TDF-based rescue therapy for more than 12 months. Suboptimal response was defined as serum HBV-DNA level of >60 IU/mL during prior rescue therapy. Multi-drug resistance was defined as the presence of two or more drug resistance-related mutations confirmed by mutation detection assay. The relationship between baseline characteristics and virologic response (HBV DNA <20 IU/mL) at 12 months were evaluated using logistic regression analysis. Results: Fifty-five patients (72.4%) were suboptimal responders to prior rescue therapy, and 26 (34.2%) had multi-drug resistance. Forty-two patients (55.3%) received combination therapy with nucleoside analogues. Virologic response at 12 months was not significantly different between the TDF monotherapy group and TDF-nucleoside analogue combination therapy group (p=0.098). The serum HBV DNA level was reduced to .4.49±1.67 log10 IU/mL in the TDF monotherapy group and to .3.97±1.69 log10 IU/mL in the TDF-nucleoside analogue combination therapy group at 12 months (p=0.18). In multivariate analysis, female sex (p=0.032), low baseline HBV-DNA level (p=0.013), and TDF monotherapy (p=0.046) were predictive factors for virologic response at 12 months. Conclusions: TDF monotherapy showed similar efficacy to that of TDF-nucleoside analogue combination therapy in patients with drug-resistant chronic hepatitis B.